Date: 20.12.2021 Your Name: Yan Li Manuscript Title: High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report Manuscript number (if known):\_\_\_\_\_TLCR-21-1039\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Shandong Key Research and Development Program (No. 2019GSF108251)	
	medical writing, article processing charges, etc.)	Technology support from Xiaoxing Su and Yan Lei of	
	No time limit for this item.	Berry Oncology	
		Corporation for	
		Bioinformatics	
		Time frame: past	36 months
2	Grants or contracts from	_x_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_x_None	
4	Consulting fees	x None	

5	Payment or honoraria for	_x_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_x_None	
	testimony		
7	Support for attending meetings and/or travel	_x_None	
8	Patents planned, issued or	_x_None	
	pending		
9	Participation on a Data	_x_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_x_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_x_None	
12	Dessist of any invest		
12	Receipt of equipment,	_x_None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	_x_None	
	financial interests		

Yan Li reports funding from the Shandong Key Research and Development Program (No. 2019GSF108251). We have received technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.

#### Please place an "X" next to the following statement to indicate your agreement:

Date: 20.12.2021 Your Name: Peng Duan Manuscript Title: High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report Manuscript number (if known):\_TLCR-21-1039\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	

4	Consulting fees	x None	
4	Consulting lees		
5	Payment or honoraria for	_x_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	x None	
-	testimony		
7	Support for attending meetings and/or travel	_x_None	
8	Patents planned, issued or	_x_None	
	pending		
9	Participation on a Data	x_None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_x_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_x_None	
12	Dessint of equipment	v. Nene	
12	Receipt of equipment, materials, drugs, medical	_x_None	
	writing, gifts or other		
	services		
13	Other financial or non-	_x_None	
	financial interests		

The author received technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.

Please place an "X" next to the following statement to indicate your agreement:

Date: 20.12.2021 Your Name: Yan Guan Manuscript Title: High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report Manuscript number (if known):\_\_\_\_TLCR-21-1039\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.	
		Timo framou pact	26 months
2		Time frame: past	So months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	x_None	

-			
5	Payment or honoraria for	_x_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_x_None	
Ĭ	testimony		
	cestimony		
-			
7	Support for attending	_x_None	
	meetings and/or travel		
8	Patents planned, issued or	x None	
0			
	pending		
9	Participation on a Data	_x_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_x_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x None	
11			
10			
12	Receipt of equipment,	_x_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_x_None	
	financial interests		

The author received technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.

### Please place an "X" next to the following statement to indicate your agreement:

Date: 20.12.2021 Your Name: Qing Chen Manuscript Title: High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report Manuscript number (if known):\_\_TLCR-21-1039\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.	
		Time from a reat	26 months
2	Grants or contracts from	Time frame: past	Sementins
Z	any entity (if not indicated in item #1 above).	_x_None	
3	Royalties or licenses	_x_None	
4	Consulting fees	_x_None	

_	-		
5	Payment or honoraria for	_x_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_x_None	
	testimony		
7	Support for attending	_x_None	
	meetings and/or travel		
	Detents planned issued or		
8	Patents planned, issued or	_x_None	
	pending		
9	Participation on a Data	_x_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_x_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x None	
12	Receipt of equipment,	x None	
1	materials, drugs, medical		
1	writing, gifts or other		
1	services		
13	Other financial or non-	x None	
	financial interests		

The author received technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.

### Please place an "X" next to the following statement to indicate your agreement:

Date 13.12.2021

Your Name: Anna Grenda

Manuscript Title: High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report

Manuscript number (if known) TLCR-21-1039

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4    Consulting fees    None	4	Consulting food	Nana
letures, presentations, speakers bureaus, manuscript writing or educational events      None        6      Payment for expert testimony      None        7      Support for attending meetings and/or travel      None        8      Patents planned, issued or pending      None        9      Paticipation on a Data Safety Monitoring Board or Advisory Board      None        10      Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      None        11      Stock or stock options      None      Image: Committee or advocacy group, paid or unpaid        12      Receipt of equipment, materials, drugs, medical writing, gifts or other services      None      Image: Committee or advocacy group, group, group, medical or non-        13      Other financial or non-      None      Image: Committee or advocacy group, grids or non-	4	Consulting fees	None
letures, presentations, speakers bureaus, manuscript writing or educational events      None        6      Payment for expert testimony      None        7      Support for attending meetings and/or travel      None        8      Patents planned, issued or pending      None        9      Paticipation on a Data Safety Monitoring Board or Advisory Board      None        10      Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      None        11      Stock or stock options      None      Image: Committee or advocacy group, paid or unpaid        12      Receipt of equipment, materials, drugs, medical writing, gifts or other services      None      Image: Committee or advocacy group, group, group, medical or non-        13      Other financial or non-      None      Image: Committee or advocacy group, grids or non-			
letures, presentations, speakers bureaus, manuscript writing or educational events      None        6      Payment for expert testimony      None        7      Support for attending meetings and/or travel      None        8      Patents planned, issued or pending      None        9      Paticipation on a Data Safety Monitoring Board or Advisory Board      None        10      Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid      None        11      Stock or stock options      None      Image: Committee or advocacy group, paid or unpaid        12      Receipt of equipment, materials, drugs, medical writing, gifts or other services      None      Image: Committee or advocacy group, group, group, medical or non-        13      Other financial or non-      None      Image: Committee or advocacy group, grids or non-			
speakers bureaus, manuscript writing or educational events      None        6      Payment for expert testimony      None        7      Support for attending meetings and/or travel      None        8      Patents planned, issued or pending      None        9      Patticipation on a Data Safety Monitoring Board or Advisory Board      None        10      Leadership or fiduciary role in other board, society, orgmittee or advocacy group, paid or unpaid      None        11      Stock or stock options writing, gifts or other services      None      Image: Comparison of the compariso	5		None
manuscript writing or educational eventsNone6Payment for expert testimonyNone7Support for attending meetings and/or travelNone7Support for attending meetings and/or travelNone8Patents planned, issued or pendingNone9Patticipation on a Data Safety Monitoring Board or Advisory BoardNone10Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaidNone11Stock or stock options writing, gifts or other servicesNone12Receipt of equipment, materials, fungs, medical writing, gifts or other servicesNone13Other financial or non-None		lectures, presentations,	
educational eventsMone6Payment for expert testimonyNone6Payment for expert testimonyNone7Support for attending meetings and/or travelNone7Support for attending meetings and/or travelNone8Patents planned, issued or pendingNone9Patents planned, issued or pendingNone9Participation on a Data Safety Monitoring Board or Advisory BoardNone10Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaidNone11Stock or stock options materials, drugs, medical writing, gifts or other servicesNone12Receipt of equipment, materials, drugs, medical writing, gifts or other servicesNone13Other financial or non-None		speakers bureaus,	
6    Payment for expert testimony    None    Image: Construction of the symptement of testimon		manuscript writing or	
testimony      Image: I		educational events	
testimony      Image: I	6	Payment for expert	None
Support for attending meetings and/or travel      None      Image: Construct of the construct o			
meetings and/or travel  Image: Section of travel    None  Image: Section of travel    Patents planned, issued or pending  None    Patricipation on a Data Safety Monitoring Board or Advisory Board  None    Image: Section of travel  Image: Section of travel    Image: Section of travel  Image: Section of travel    Ima		,	
meetings and/or travel  Image: Section of travel    None  Image: Section of travel    Patents planned, issued or pending  None    Patricipation on a Data Safety Monitoring Board or Advisory Board  None    Image: Section of travel  Image: Section of travel    Image: Section of travel  Image: Section of travel    Ima	7	Support for attending	None
None      Image: Mone        8      Patents planned, issued or pending      None      Image: Mone      Imag	,		
pendingImage: Image: Image		meetings and/or traver	None
pendingImage: Image: Image			
pendingImage: Image: Image			
pendingImage: Image: Image			
9Participation on a Data Safety Monitoring Board or Advisory BoardNoneImage: Constraint of the state of the st	8	-	None
Safety Monitoring Board or Advisory BoardImage: Image: Im			
Safety Monitoring Board or Advisory BoardImage: Image: Im			
Safety Monitoring Board or Advisory BoardImage: Image: Im	9	Participation on a Data	None
Advisory BoardImage: Construction of the function of		Safety Monitoring Board or	
10Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaidNone11Stock or stock optionsNone11Stock or stock optionsNone12Receipt of equipment, materials, drugs, medical writing, gifts or other servicesNone13Other financial or non-None			
in other board, society, committee or advocacy group, paid or unpaidImage: Image:	10		None
committee or advocacy group, paid or unpaidMone11Stock or stock optionsNone12Receipt of equipment, materials, drugs, medical writing, gifts or other servicesNone13Other financial or non-None	10		
group, paid or unpaid    Image: Mone      11    Stock or stock options    None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other services    None      13    Other financial or non-    None			
11    Stock or stock options    None    Image: Constraint of the stock options      12    Receipt of equipment, materials, drugs, medical writing, gifts or other services    None    Image: Constraint of the stock options      13    Other financial or non-    None    Image: Constraint of the stock options		-	
Image: services  Image: service  Image: service  Image: service    13  Other financial or non-  None	11		None
materials, drugs, medical writing, gifts or other services  Image: Constraint of the services    13  Other financial or non-  None			
materials, drugs, medical writing, gifts or other services  Image: Constraint of the services    13  Other financial or non-  None			
materials, drugs, medical writing, gifts or other services  Image: Constraint of the services    13  Other financial or non-  None	12	Dessist of a subsequent	
writing, gifts or other services	12		None
services  None    13  Other financial or non-  None			
13  Other financial or non-  None			
financial interests	13		None
		financial interests	

The author received technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.

#### Please place an "X" next to the following statement to indicate your agreement:

Date:07.12.2021	
Your Name:	Petros Christopoulos
Manuscript Title:	Good efficacy of alectinib in a case of advanced lung adenocarcinoma two rare ALK fusions: HIP1-
ALK and LTBP1-ALK	
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Roche Takeda AstraZeneca Novartis	research grant (to institution) research grant (to institution) research grant (to institution) research grant (to institution)
3	Royalties or licenses	xNone	
4	Consulting fees	xNone	

5	Payment or honoraria for	Roche	speaker's honoraria to myself
J	lectures, presentations, speakers bureaus,	Takeda	speaker's honoraria to myself
		AstraZeneca	speaker's honoraria to myself
	manuscript writing or	Novartis	speaker's honoraria to myself
	educational events		, , ,
6	Payment for expert	_xNone	
	testimony		
7	Support for attending meetings and/or travel	AstraZeneca	to myself
		Takeda	to myself
		Novartis	to myself
		Eli Lilly	to myself
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	Pfizer	advisory board
		Chugai	advisory board
		Boehringer Ingelheim	advisory board
		Roche	advisory board
10	Leadership or fiduciary role	_xNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
11			
12	Receipt of equipment, materials, drugs, medical	x None	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

Petros Christopoulos has received research funding from AstraZeneca, Novartis, Roche, and Takeda, speaker's honoraria from AstraZeneca, Novartis, Roche, Takeda, support for attending meetings from AstraZeneca, Eli Lilly, Novartis, Takeda, and personal fees for participating to advisory boards from Boehringer Ingelheim, Chugai, Pfizer and Roche, all outside the submitted work. We have received technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.

#### Please place an "X" next to the following statement to indicate your agreement:

Date: \_\_\_\_\_12/17/2021\_\_\_\_\_\_ Your Name: \_\_\_\_Marc G DENIS\_\_\_\_\_\_ Manuscript Title: \_ Significant efficacy of alectinib on a patient with advanced lung adenocarcinoma with two rare ALK fusion site \_\_\_\_\_\_

Manuscript number (if known):\_TLCR-21-1039\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.		
	Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone		
3	Royalties or licenses	x None		

4	Consulting fees	x None	
5	Payment or honoraria for	x_None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	x None	
•	testimony		
	-		
7	Support for attending	x_None	
	meetings and/or travel		
8	Patents planned, issued or	x_None	
	pending		
9	Participation on a Data	x None	
5	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	x None	
11	SLOCK OF SLOCK OPTIONS		
12	Receipt of equipment,	x_None	
	materials, drugs, medical		
	writing, gifts or other		
10	services	v. Nere	
13	Other financial or non- financial interests	x_None	

The author received technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.

Please place an "X" next to the following statement to indicate your agreement:

Date: 20.12.2021 Your Name: Qisen Guo Manuscript Title: High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report Manuscript number (if known):\_\_\_\_\_TLCR-21-1039\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Shandong Key Research and Development Program (No. 2019GSF108251)	
		Technology support from Xiaoxing Su and Yan Lei of Berry Oncology	
		Corporation for Bioinformatics.	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	_x_None	
	in item #1 above).		
3	Royalties or licenses	_x_None	
4	Consulting fees	_x_None	

5	Payment or honoraria for	_x_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	_x_None	
7	Support for attending	_x_None	
	meetings and/or travel		
8	Patents planned, issued or	x_None	
0	pending		
	pending		
9	Participation on a Data	x None	
9	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	y None	
10	in other board, society,	_x_None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_x_None	
12	Receipt of equipment,	_x_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	3 Other financial or non- financial interests	_x_None	

Qisen Guo reports funding from the Shandong Key Research and Development Program (No. 2019GSF108251). We have received technology support from Xiaoxing Su and Yan Lei of Berry Oncology Corporation for Bioinformatics.

#### Please place an "X" next to the following statement to indicate your agreement: